Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by CAIN, P. A.
Right arrow Articles by ELLIS, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CAIN, P. A.
Right arrow Articles by ELLIS, F. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1977, Vol. 49, No. 9 941-944
© 1977 The Board of Management and Trustees of the British Journal of Anaesthesia

other

ANAESTHESIA FOR PATIENTS SUSCEPTIBLE TO MALIGNANT HYPERPYREXIA

A study of pancuronium and methylprednisolone

P. A. CAIN, M.B., CH.B., F.F.A.R.C.S. and F. R. ELLIS, M.B., CH.B., PH.D., F.F.A.R.C.S.

Department of Anaesthesia, University of Leeds

In a study of human malignant hyperpyrexia-susceptible muscle a comparison between pancuronium and methylprednisolone showed that both drugs produced qualitatively similar depression of the halothane-induced muscle contracture. From this and other evidence, it is suggested that pancuronium is a suitable drug for use in malignant hyperpyrexia-susceptible patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.